Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(10):705-707; doi:10.1093/jnci/dji152
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Narazaki, M.
Right arrow Articles by Tosato, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Narazaki, M.
Right arrow Articles by Tosato, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

Targeting Coagulation to the Tumor Microvasculature: Perspectives and Therapeutic Implications From Preclinical Studies

Masashi Narazaki, Giovanna Tosato

Affiliation of authors: Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

Correspondence to: Giovanna Tosato, MD, Bldg. 10, 12C205, 10 Center Dr., Bethesda, MD 20892 (e-mail: tosatog@mail.nih.gov).

The first 10% of the full text of this article appears below.

Pioneering studies at the National Cancer Institute by Glenn Algire in 1945 led to the conclusion that "the rapid growth of tumor explants is dependent on the development of a rich vascular supply" (1). There is now little doubt that most tumors are dependent on neovascularization for oxygen and nutrients to sustain progressive growth (2). In 1971, Judah Folkman (3) proposed the innovative idea that angiogenesis inhibitors could be used to treat cancer. In 2004, the U.S. Food and Drug Administration approved the first antiangiogenic drug for the treatment of cancer, a humanized monoclonal antibody against VEGF-A named Avastin (bevacizumab). Other drugs in this category are under development.

There are at . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
A. Fleischmann, B. Waser, and J. C. Reubi
High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications
Endocr. Relat. Cancer, June 1, 2009; 16(2): 623 - 633.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
R. D. Ward, B. M. Stone, L. T. Raetzman, and S. A. Camper
Cell Proliferation and Vascularization in Mouse Models of Pituitary Hormone Deficiency
Mol. Endocrinol., June 1, 2006; 20(6): 1378 - 1390.
[Abstract] [Full Text] [PDF]